Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E17.93 EPS (ttm)3.34 Insider Own0.10% Shs Outstand1.64B Perf Week-0.25%
Market Cap98.25B Forward P/E10.65 EPS next Y5.62 Insider Trans-19.73% Shs Float1.60B Perf Month-2.22%
Income5.48B PEG1.09 EPS next Q1.20 Inst Own71.00% Short Float1.66% Perf Quarter7.71%
Sales23.78B P/S4.13 EPS this Y185.20% Inst Trans0.02% Short Ratio3.21 Perf Half Y4.25%
Book/sh2.87 P/B20.86 EPS next Y18.11% ROA10.20% Target Price70.00 Perf Year-11.07%
Cash/sh5.24 P/C11.42 EPS next 5Y16.39% ROE115.60% 52W Range44.55 - 69.54 Perf YTD3.09%
Dividend2.28 P/FCF23.74 EPS past 5Y3.50% ROI16.90% 52W High-13.92% Beta1.49
Dividend %3.81% Quick Ratio1.40 Sales past 5Y7.90% Gross Margin79.80% 52W Low34.37% ATR1.41
Employees28000 Current Ratio1.60 Sales Q/Q18.20% Oper. Margin34.20% RSI (14)43.97 Volatility1.72% 2.02%
OptionableYes Debt/Eq6.87 EPS Q/Q31.10% Profit Margin23.00% Rel Volume1.19 Prev Close61.31
ShortableYes LT Debt/Eq6.35 EarningsJul 29 BMO Payout64.30% Avg Volume8.26M Price59.86
Recom2.30 SMA20-2.89% SMA50-2.42% SMA2004.44% Volume9,867,049 Change-2.37%
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Jun-25-16 12:01AM  [$$] U.S. Cheese Prices Fall at
Jun-24-16 04:56PM  2 Key FDA Actions On Potential Blockbuster Drugs Next Week
12:54PM  AbbVie, Inc. : ABBV-US: Dividend Analysis : July 15th, 2016 (record date) : By the numbers : June 24, 2016
Jun-21-16 03:03PM  7 Pharmaceutical Stocks With Dividends Yielding More Than 3% at Motley Fool
Jun-20-16 01:00PM  Volatility Ramps Up and Spreads Reverse Course
09:06AM  CORRECTED (OFFICIAL)-Novartis aims to nearly triple biosimilar drugs on market by 2020 Reuters
08:00AM  AbbVie Teams Up with Leading Nonprofit Organizations to Give Back to Underserved Local Communities PR Newswire
Jun-19-16 06:06PM  Better Buy: AbbVie Inc. vs. Johnson & Johnson at Motley Fool
06:01PM  Novartis aims to nearly triple biosimilar drugs on market by 2020 Reuters
10:15AM  6 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Jun-16-16 12:53PM  AbbVie Declares Quarterly Dividend PR Newswire
08:00AM  AbbVie Scholarship Programs Recognize Exceptional Students Living with Chronic Inflammatory Diseases PR Newswire
06:01AM  [$$] Infinity Pharmaceuticals' Disappointing Data at
Jun-15-16 04:19PM  One Reason Why AbbVie (ABBV) Stock Closed Up Today
03:30PM  Infinity Pharmaceuticals Faces Downgrades as Drug Results Disappoint
02:51PM  AbbVie: Low Expectations, Cheap Valuation, What's Not to Love? at
11:05AM  6 Biopharma Movers Making a Run on Wednesday at 24/7 Wall St.
09:45AM  Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data
Jun-14-16 12:45PM  Why Infinity Pharmaceuticals Inc. Is Being Obliterated Today at Motley Fool
11:15AM  Why Infinity Pharmaceuticals Crashed at 24/7 Wall St.
Jun-13-16 04:35PM  Agios Upgraded As Anemia Drug Data Soothes Safety Concerns
02:37PM  AbbVie, Inc. Value Analysis (NYSE:ABBV) : June 13, 2016
08:50AM  Portfolio managers spotlighting these three hot sectors at CNBC
08:15AM  Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference at 24/7 Wall St.
08:01AM  Former Fed President: All My Very Rich Friends Are Holding a Lot of Cash
07:30AM  [$$] Billions at Stake as Biotech-Copycat Startups Chase Pharma Giants at The Wall Street Journal
Jun-11-16 12:01PM  My Favorite Clinical-Stage Biotech Stocks to Buy at Motley Fool
10:46AM  AbbVie's Rova-T Update at ASCO: Good or Bad? at Motley Fool
Jun-10-16 06:42PM  5 Appealing Biotechnology Stocks for Healthy Long-term Returns
04:07PM  Amazon Is A Buy; Applied Materials Target Hiked; AbbVie Downgraded
03:42PM  Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure at Motley Fool
02:13PM  BMO Cuts AbbVie To Hold On Pipeline Uncertainty at
12:11PM  Abbvie (ABBV) Stock Downgraded at BMO Capital
10:19AM  [$$] Bristol-Myers, a Top Pharmaceuticals Pick at
09:15AM  Incyte's Jakafi Positive in Phase III for Polycythemia Study
09:06AM  An Inside Look at Incytes Product Portfolio
09:05AM  Top Analyst Upgrades and Downgrades: Abbvie, Amazon, Cliffs Natural, Corning, Dynegy, Joy Global, Stanley Black & Decker and More at 24/7 Wall St.
08:19AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : June 10, 2016
08:10AM  Analysts' Actions -- AbbVie, Corning, J.M. Smucker, Mattress Firm and More
08:05AM  Major Pharma Has Short Sellers on the Run at 24/7 Wall St.
Jun-09-16 04:21PM  Why Galapagos NV Shares Soared 30.5% in May at Motley Fool
10:41AM  3 Reasons to Buy AbbVie Inc. at Motley Fool
Jun-08-16 05:09PM  AbbVie Stock Downgraded As Worlds Best-Selling Drug Faces Rivals
05:08PM  [$$] Steel stocks rise on 'very bullish' hopes at Financial Times
05:07PM  ABBVIE INC. Files SEC form 8-K, Temporary Suspension of Trading Under Registrant's Employee Benefit Plans, Financial
02:38PM  Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
01:38PM  AbbVie (ABBV) Stock Slides on Ratings Downgrade
11:58AM  AbbVie: Four Reason to Cut and Run at
08:40AM  Morning Movers: AK Steel Jumps on Upgrade; Lululemon Rises at
05:59AM  AbbVie downgraded by Morgan Stanley
Jun-07-16 05:30PM  3 Dividend Aristocrats to Buy in June at Motley Fool
11:40AM  Biogen: 'Major Upside Opportunity Gone' at
10:06AM  Goldman's Kostin on rate hike
09:00AM  New AbbVie Global Campaign Aims to Provide Educational Resources for Millions Living with Painful, Chronic Skin Disease PR Newswire
08:25AM  4 Jefferies Franchise List Dividend Stocks to Buy Now at 24/7 Wall St.
Jun-06-16 07:21PM  Weekly CEO Sells Highlight
07:00PM  Hunting growth, Samsung races to get up to speed on biosimilar drugs
06:49PM  AbbVie shares stumble after downgrade, news report at CNBC
05:37PM  AbbVie Breakout Failing As Cancer Drug Data From $5.8 Billion Buy Disappoint
01:58PM  AbbVie Gears Up for an Even Higher Run
01:40PM  How Credit Suisse Views Major Pharma After ASCO at 24/7 Wall St.
12:37PM  Why Adamis Pharmaceuticals, Immunomedics and Three Other Stocks Are Deep in Red Today? at Insider Monkey
12:24PM  Bristol-Myers Hits 17-Year High Showing Off Cancer Portfolio
11:21AM  AbbVie at ASCO: Early-Stage Data on ABT-414 and Rova-T
11:13AM  AbbVie: It's Complicated at
10:36AM  Winners And Losers From Cancer Research's Big Event at Forbes
10:01AM  3 Cheap Biotech Stocks You Can Buy Now at Motley Fool
09:58AM  Why AbbVie (ABBV) Stock Is Falling Today
09:00AM  AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual PR Newswire
08:44AM  Morning Movers: AbbVie Tumbles on Trial; Wal-Mart Climbs on Upgrade at
08:42AM  What AbbVie Bought for $5.8 Billion at Motley Fool
01:00AM  ABBV, JNJ, AGN: Jim Cramer's Views
Jun-05-16 09:12AM  [$$] New cancer drugs target deadliest forms of the disease at Financial Times
09:00AM  AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting PR Newswire
07:30AM  Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC) PR Newswire
07:30AM  AbbVies Lung Cancer Drug Shows Some Benefit in Human Trial at Bloomberg
Jun-04-16 10:43AM  Is AbbVie's Stock Too Risky? at Motley Fool
Jun-03-16 07:02PM  Cramer: Many Portfolio Managers Hope for the 'Wrong' Jobs Number
03:05PM  3 Reasons AbbVie's and Biogen's Latest MS Drug Might Flop at Motley Fool
01:42PM  AbbVie To Present An OVerview Of Pipeline, Reinforcing Tactics Of Delivering New Therapies
08:00AM  AbbVie to Highlight its Innovative Pipeline to the Investment Community PR Newswire
Jun-02-16 05:58PM  Final Trade: Under Armour, Abbvie, & more
05:08PM  Investing Action Plan For Friday: Jobs, Merck, Bristol-Myers, Lilly
03:07PM  Why does Biogen need a sixth drug for multiple sclerosis? at
09:57AM  2 Top Stocks for Retirees at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
09:24AM  ABBVIE INC. Files SEC form 8-K, Other Events
09:00AM  AbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016) PR Newswire
05:05AM  [$$] M&A back on the table as 'big pharma' targets smaller rivals at Financial Times
Jun-01-16 02:40PM  Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
12:58PM  Biotech's big rebound
09:45AM  ABBVIE INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Secur
09:08AM  [$$] Cancer doctors face next drug challenge at Financial Times
May-31-16 04:26PM  3 Reasons Not to Worry About High Corporate Debt Levels at
09:25AM  FDA Approves Biogen and AbbVie's MS Treatment at Investopedia
09:06AM  Understanding Bristol-Myers Squibbs Other Segments
08:16AM  Merck, AbbVie & Amgen Drugs a Step Closer to EU Approval
08:00AM  AbbVie to Present at the Goldman Sachs 37th Annual Global Healthcare Conference PR Newswire
07:23AM  AbbVie Gets Europe's Approval For IMBRUVICA For Chronic Lymphocytic Leukemia Treatment
06:00AM  European Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia PR Newswire
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics, Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Option Exercise35.8865,0002,332,200538,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.2440,0212,851,264473,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.0924,9791,775,656513,208Jul 31 05:41 PM